This study was published in the Archives of Ophthalmology 2006 Jan;124(1):33-7
Study title and authors:
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study.
Study title and authors:
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study.
McGwin G Jr, Modjarrad K, Hall TA, Xie A, Owsley C.
Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Suite 609, 700 S. 18th Street, Birmingham, AL 35294-0009, USA. mcgwin@uab.edu
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16401782/
Department of Ophthalmology, School of Medicine, University of Alabama at Birmingham, Suite 609, 700 S. 18th Street, Birmingham, AL 35294-0009, USA. mcgwin@uab.edu
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/16401782/
The objective of the study was to evaluate both the use of cholesterol-lowering medications as a group and the use of statins specifically with regard to the risk of age-related macular degeneration. The study included 2,755 men and women aged over 65 years.
The study found:
(a) Those taking cholesterol-lowering medications had a 35% increased risk of age-related macular degeneration compared to those not taking cholesterol-lowering medications.
(b) Those taking statins had a 40% increased risk of age-related macular degeneration compared to those not taking statins.
McGwin concluded: "Statin use might increase the risk of age-related macular degeneration".